![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri ...
1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant ...
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
Key Points: 1. Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain ...
1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Click here to read this article in JAMA Internal Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...
1. Compared with using only using a GLP-1 receptor agonist or an SGLT-2 inhibitor, combination therapy with both drug classes ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
